Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown(Dana-Farber Cancer Institute), Farrukh T. Awan(The University of Texas Southwestern Medical Center), Jason Jiang(Sanofi (United States)), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Coumaran Égile(AstraZeneca (United Kingdom)), Matthew S. Davids(Dana-Farber Cancer Institute), Pau Abrisqueta(Universitat Autònoma de Barcelona), Siddha Kasar(AVEO Oncology (United States)), Joanne Lager(AVEO Oncology (United States))
Cited by 55
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752